ZYVOX should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist1.
ZYVOX offers effective intervention for nosocomial pneumonia, community acquired pneumonia and complicated skin and soft tissue infections caused by susceptible Gram positive pathogens1
- ZYVOX is active against Gram positive, aerobic and anaerobic pathogens, including staphylococci, enterococci and streptococci1.
- ZYVOX is not active against infections caused by Gram negative pathogens1.
|Susceptible Organisms||Resistant Organisms|
Coagulase negative staphylococci
Group C streptococci
Group G streptococci
*Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications. Whereas linezolid shows some in vitro activity against Legionella, Chlamydia pneumoniae and Mycoplasma pneumoniae, there are insufficient data to demonstrate clinical efficacy.
Table adapted from ZYVOX Summary of Product Characteristics1.
- ZYVOX® Summary of Product Characteristics